ATE401061T1 - Mehrschichtige tablette mit pravastatin und aspirin und verfahren - Google Patents

Mehrschichtige tablette mit pravastatin und aspirin und verfahren

Info

Publication number
ATE401061T1
ATE401061T1 AT03812825T AT03812825T ATE401061T1 AT E401061 T1 ATE401061 T1 AT E401061T1 AT 03812825 T AT03812825 T AT 03812825T AT 03812825 T AT03812825 T AT 03812825T AT E401061 T1 ATE401061 T1 AT E401061T1
Authority
AT
Austria
Prior art keywords
aspirin
layer containing
pravastatin
tablet containing
layer tablet
Prior art date
Application number
AT03812825T
Other languages
English (en)
Inventor
Loutfy Benkerrour
Olivier Galley
Francoise Quinet
Peter Timmins
Admassu Abebe
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32505946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE401061(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE401061T1 publication Critical patent/ATE401061T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03812825T 2002-12-11 2003-12-03 Mehrschichtige tablette mit pravastatin und aspirin und verfahren ATE401061T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/316,424 US20040115265A1 (en) 2002-12-11 2002-12-11 Multilayered tablet containing pravastatin and aspirin and method

Publications (1)

Publication Number Publication Date
ATE401061T1 true ATE401061T1 (de) 2008-08-15

Family

ID=32505946

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03812825T ATE401061T1 (de) 2002-12-11 2003-12-03 Mehrschichtige tablette mit pravastatin und aspirin und verfahren

Country Status (17)

Country Link
US (1) US20040115265A1 (de)
EP (1) EP1581194B1 (de)
JP (1) JP2006511520A (de)
AT (1) ATE401061T1 (de)
AU (1) AU2003297689A1 (de)
CY (1) CY1108414T1 (de)
DE (1) DE60322264D1 (de)
DK (1) DK1581194T3 (de)
ES (1) ES2308040T3 (de)
IS (1) IS2877B (de)
MY (1) MY140947A (de)
NO (1) NO338696B1 (de)
PL (1) PL206190B1 (de)
PT (1) PT1581194E (de)
SI (1) SI1581194T1 (de)
TW (1) TWI361700B (de)
WO (1) WO2004052289A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2350327C2 (ru) 2003-04-29 2009-03-27 Ориксиджен Серапьютикс, Инкорпорэйтд Составы, вызывающие потерю веса
US8163797B2 (en) * 2003-12-31 2012-04-24 Actavis Elizabeth Llc Method of treating with stable pravastatin formulation
WO2006072054A1 (en) * 2004-12-30 2006-07-06 Genzyme Corporation Zinc-containing treatments for hyperphosphatemia
US20060251722A1 (en) * 2005-05-03 2006-11-09 Novavax, Inc. Multi-component vitamin and mineral supplement for the optimal absorption of components
JP2009507019A (ja) * 2005-09-02 2009-02-19 ジェンザイム・コーポレーション リン酸塩を除去する方法およびそれに使用される重合体
BRPI0618352A2 (pt) * 2005-11-08 2011-08-23 Genzyme Corp composições farmacêuticas e métodos de tratamento da hiperfosfatemia em um paciente
EP1951212A2 (de) 2005-11-22 2008-08-06 Orexigen Therapeutics, Inc. Zusammensetzungen und verfahren zur erhöhung der insulinsensitivität
WO2007072060A2 (en) * 2005-12-23 2007-06-28 Cipla Limited Particles comprising a core containing a hmg-coa reductase inhibitor and coated with a film
WO2007073702A2 (es) 2005-12-29 2007-07-05 Osmotica Corp. Comprimido multicapa con combinación de triple liberación
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
JP2009542653A (ja) * 2006-07-05 2009-12-03 ジェンザイム コーポレーション リン酸塩過剰血症のための鉄（ｉｉ）含有治療剤
US8765178B2 (en) * 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
TW201811315A (zh) * 2006-11-09 2018-04-01 美商歐瑞根治療有限公司 層狀醫藥調配物
CA2668885C (en) 2006-11-09 2016-08-02 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
ES2579229T3 (es) 2007-03-13 2016-08-08 Jds Therapeutics, Llc Procedimientos y composiciones para la liberación sostenida de cromo
WO2009002867A2 (en) * 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
LT2207526T (lt) 2007-10-12 2018-02-12 Ferring International Center S.A. Farmacinio produkto, apimančio citrinų rūgštį, magnio oksidą, kalio bikarbonatą ir natrio pikosulfatą, gavimo būdas, farmacinės kompozicijos, apimančios granules, gautas šiuo būdu, ir jų tarpiniai produktai
EP2303025A4 (de) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc Verfahren zur behandlung von eingeweidefettbeschwerden
EP3659604A1 (de) 2010-01-11 2020-06-03 Nalpropion Pharmaceuticals, Inc. Verfahren zur bereitstellung einer gewichtsverlusttherapie für patienten mit schweren depressionen
TR201005325A2 (tr) 2010-06-30 2012-01-23 Bi̇lgi̇ç Mahmut Atorvastatin ve aspirin içeren farmasötik formülasyonlar
KR20120068277A (ko) * 2010-12-17 2012-06-27 한미사이언스 주식회사 ＨＭＧ－ＣｏＡ 환원효소 억제제 및 아스피린을 포함하는 약제학적 복합제제
CN104898652B (zh) * 2011-01-28 2018-03-13 英塔茨科技公司 与一个可移动的远程机器人相互交流
PT3730132T (pt) 2012-06-06 2022-08-16 Nalpropion Pharmaceuticals Llc Composição para utilização num método de tratamento de excesso de peso e obesidade em doentes com alto risco cardiovascular
EP2810644A1 (de) 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Orale Formulierung zur Behandlung von Herz-Kreislauf-Erkrankungen
AU2017217466A1 (en) 2016-02-11 2018-08-23 Nutrition 21, Llc Chromium containing compositions for improving health and fitness
JP7109748B2 (ja) * 2018-12-11 2022-08-01 日本ジェネリック株式会社 アジルサルタンとアムロジピンベシル酸塩含有固形製剤及び固形製剤の製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590183A (en) * 1985-04-22 1986-05-20 Sterling Drug Inc. Gastric cytoprotection with sodium thiosulfate in oral administration of aspirin
JP3172749B2 (ja) * 1992-02-17 2001-06-04 ライオン株式会社 イブプロフェン含有製剤
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
IT1264517B1 (it) * 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
AP1224A (en) * 1998-03-19 2003-11-14 Bristol Myers Squibb Co Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin

Also Published As

Publication number Publication date
AU2003297689A8 (en) 2004-06-30
CY1108414T1 (el) 2014-02-12
EP1581194A2 (de) 2005-10-05
US20040115265A1 (en) 2004-06-17
WO2004052289A3 (en) 2005-03-24
TW200505432A (en) 2005-02-16
EP1581194B1 (de) 2008-07-16
DE60322264D1 (de) 2008-08-28
PL206190B1 (pl) 2010-07-30
JP2006511520A (ja) 2006-04-06
NO20052734L (no) 2005-07-07
WO2004052289A2 (en) 2004-06-24
IS2877B (is) 2014-04-15
IS7889A (is) 2005-06-10
PL377265A1 (pl) 2006-01-23
NO20052734D0 (no) 2005-06-07
MY140947A (en) 2010-02-12
DK1581194T3 (da) 2008-10-20
TWI361700B (en) 2012-04-11
NO338696B1 (no) 2016-10-03
EP1581194A4 (de) 2006-03-15
ES2308040T3 (es) 2008-12-01
SI1581194T1 (sl) 2008-12-31
AU2003297689A1 (en) 2004-06-30
PT1581194E (pt) 2008-09-24

Similar Documents

Publication Publication Date Title
CY1108414T1 (el) Δισκιο πολλαπλων στρωματων που περιεχει πραβαστατινη και ασπιρινη και μεθοδος
Reidenberg Drug discontinuation effects are part of the pharmacology of a drug
ATE279915T1 (de) Mehrschichttablette zur verabreichung einer fixen kombination von tramadol und diclofenac
AU2003251642A1 (en) Laser markable carrier unit
CL2008000489A1 (es) Metodo para ajustar el perfil de los niveles en sangre o la permeacion de un farmaco desde una composicion; y composicion para la administracion transdermica que comprende a dicho farmaco y un vehiculo farmaceuticamente aceptable.
AR017749A1 (es) Estructura de multiples estratos
GB2422721B (en) Split barrier layer including nitrogen-containing portion and oxygen-containing portion
AU2003236831A1 (en) Materials containing multiple layers of vesicles
PE20000349A1 (es) Composicion farmaceutica que contiene una combinacion de una estatina y aspirina
EA200700977A1 (ru) Двуслойная таблетка, содержащая телмисартан и амлодипин
AU2003303377A1 (en) Vapor deposited titanium and titanium-nitride layers for dental devices
HUP0001948A2 (hu) Szimmetrikus, többrétegű rétegszerkezet, valamint eljárás szimmetrikus, többrétegű rétegszerkezet előállítására
DK0649370T3 (da) Beholder med oxygenbarriere
AU2003234610A1 (en) Higher layer bonding of multiple access lines for carrier grade access
ATE374425T1 (de) Zweilagige schutzschicht
EA200700765A1 (ru) Двуслойная таблетка
DE69937898D1 (de) Mehrschichtige Tablette, enthaltend Rosiglitazone
AU2003244210A1 (en) Reduced-reflection film having low-refractive-index layer
AU2003285237A8 (en) Barrier layer for thick film dielectric electroluminescent displays
AU2003255450A1 (en) Polyolefin multilayered film, method for the production of said film and use thereof
BR0104185A (pt) Embalagem retorta flexìvel que não é à base de folha
TH69755A (th) ยาเม็ดชนิดหลายชั้นซึ่งมีพราวาสเตติน และแอสไพริน และวิธี
Sowers Stroke in patients with diabetes
AU2002227815A1 (en) Insertion layer for thick film electroluminescent displays
GT199800174A (es) Estructura absorbente en capas.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1581194

Country of ref document: EP